The use of agents stimulating erythropoiesis allows to achieve the target values of hemoglobin and hematocrit in patients with pre-dialysis CKD stages. Our research has shown that LVH is already developing in the conservative stages of CKD. At the same time, anemia can act as an additional pathogenetic factor in the development of LVH. In addition, the role of arterial hypertension as a risk factor for LVH in patients with CKD was confirmed, and a link was found between LVH and the level of CAD, cAD, pulse BP and age of patients.
"PATHOGENETIC JUSTIFICATION OF THE CORRECTION OF ANEMIA IN PATIENTS WITH CHRONIC DISEASES,"
Central Asian Journal of Pediatrics: Vol. 2
, Article 25.
Available at: https://uzjournals.edu.uz/pediatrics/vol2/iss1/25